

# Postmenopausal hormone therapy and Alzheimer's disease, dementia, and Parkinson's disease: A systematic review and time-response meta-analysis

Wu, M., Li, M., Yuan, J., Liang, S., Chen, Z., Ye, M., Ryan, P. M., Clark, C., Tan, S. C., Rahmani, J., Varkaneh, H. K. & Bhagavathula, A. S.

Author post-print (accepted) deposited by Coventry University's Repository

## Original citation & hyperlink:

Wu, M, Li, M, Yuan, J, Liang, S, Chen, Z, Ye, M, Ryan, PM, Clark, C, Tan, SC, Rahmani, J, Varkaneh, HK & Bhagavathula, AS 2020, 'Postmenopausal hormone therapy and Alzheimer's disease, dementia, and Parkinson's disease: A systematic review and time-response meta-analysis', *Pharmacological Research*, vol. 155, 104693.

<https://dx.doi.org/10.1016/j.phrs.2020.104693>

DOI 10.1016/j.phrs.2020.104693

ISSN 1043-6618

Publisher: Elsevier

**NOTICE: this is the author's version of a work that was accepted for publication in *Pharmacological Research*. Changes resulting from the publishing process, such as peer review, editing, corrections, structural formatting, and other quality control mechanisms may not be reflected in this document. Changes may have been made to this work since it was submitted for publication. A definitive version was subsequently published in *Pharmacological Research*, 155, (2020) DOI: 10.1016/j.phrs.2020.104693**

© 2020, Elsevier. Licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International <http://creativecommons.org/licenses/by-nc-nd/4.0/>

Copyright © and Moral Rights are retained by the author(s) and/ or other copyright owners. A copy can be downloaded for personal non-commercial research or study, without prior permission or charge. This item cannot be reproduced or quoted extensively from without first obtaining permission in writing from the copyright holder(s). The content must not be changed in any way or sold commercially in any format or medium without the formal permission of the copyright holders.

**This document is the author's post-print version, incorporating any revisions agreed during the peer-review process. Some differences between the published version and this version may remain and you are advised to consult the published version if you wish to cite from it.**

# **Postmenopausal hormone therapy and Alzheimer's disease, dementia, and Parkinson's disease: a systematic review and time-response meta-analysis**

Minghua Wu <sup>a,b\*</sup>, Min Li <sup>a,b</sup>, Jun Yuan <sup>a,b</sup>, Sen Liang <sup>a,b</sup>, Zhaoyao Chen <sup>a,b</sup>, Min Ye<sup>c\*</sup>, Paul M Ryana, Cain Clarke<sup>e</sup>, Shing Cheng Tan<sup>f</sup>, Jamal Rahmani<sup>g</sup>, Hamed kord Varkaneh<sup>g</sup>, Akshaya Srikanth Bhagavathula<sup>h</sup>

<sup>a</sup> Department of neurology, Jiangsu Province Hospital of Chinese Medicine, 55 Hanzhong, Nanjing, Jiangsu Province, 210029, China

<sup>b</sup> The Affiliated Hospital of Nanjing University of Chinese Medicine, 55 Hanzhong, Nanjing, Jiangsu Province, 210029, China

<sup>c</sup> Department of Neurology, Affiliated BenQ Hospital of Nanjing Medical University, Nanjing, Jiangsu Province, 210019, China

<sup>d</sup> School of Medicine, University College Cork, Cork, Ireland

<sup>e</sup> School of Life Sciences, Coventry University, Coventry, CV1 5FB, United Kingdom

<sup>f</sup> UKM Medical Molecular Biology Institute, Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia

<sup>g</sup> Department of Clinical Nutrition and Dietetics, Faculty of Nutrition and Food Technology, National Nutrition and Food Technology Research Institute, Shahid Beheshti University of Medical Sciences, Tehran, Iran

<sup>h</sup> Department of internal medicine, College of Medicine and Health Sciences, UAE University, Al Ain, UAE

\*Address correspondence to: First Corresponding author, Minghua Wu (sebastian80.n.ut@gmail.com), The Affiliated Hospital of Nanjing University of Chinese Medicine, 55 Hanzhong, Nanjing, Jiangsu Province, 210029, China. Second Corresponding author, Min Ye (yemin197001@sina.com), Department of Neurology, Affiliated BenQ Hospital of Nanjing Medical University, Nanjing, Jiangsu Province, 210019, China

**Funding:** This study was supported by grants from the the Jiangsu Province Administration of Chinese Medicine (ZX2016A2); 333 high level talents training project in Jiangsu(BRA2016507). Jiangsu Province Hospital of Chinese Medicine (y2018rc15).

**Conflict of interest:** The authors declare no conflict of interest.

**Author contributions:** Analysis, JR and HKV; Writing, SCT, CC, ASB, and PMR; Screening and Data extracting, ML, JY, SL, ZC; Idea and Manuscript revision, MW and MY.

## **Abstract**

Hormone therapy continues to be a favourable option in the management of menopausal symptomatology, but the associated risk-benefit ratios with respect to neurodegenerative diseases remain controversial. The study aim was to determine the relation between menopausal hormone

therapy and Alzheimer's disease, dementia, and Parkinson's disease in human subjects. A literature search was performed in PubMed/Medline, Cochrane collaboration, and Scopus databases from onset of the database to September 2019. Random-effects model was used to estimate pooled odd ratio (OR) and 95% confidence intervals (CI). Subgroup analysis was performed based on the type and formulation of hormone. In addition, the time-response effect of this relationship was also assessed based on duration of hormone therapy. Associations between hormone therapy and Alzheimer's disease, dementia, and Parkinson's disease in menopausal women were reported in 28 studies. Pooled results with random effect model showed a significant association between hormone therapy and Alzheimer's disease (OR 1.08, 95% CI 1.03 -1.14, I<sub>2</sub>: 69%). This relationship was more pronounced in patients receiving the combined estrogen-progestogen formulation. Moreover, a significant non-linear time-response association between hormone therapy and Alzheimer's disease was also identified (Coef<sub>1</sub> = 0.0477, p<sub>1</sub><0.001; Coef<sub>2</sub> = -0.0932, p<sub>2</sub><0.001). Similarly, pooled analysis revealed a significant association between hormone therapy and all-cause dementia (OR 1.16, 95% CI 1.02 -1.31, I<sub>2</sub>: 19%). Interestingly, no comparable relationship was uncovered between hormone therapy as a whole and Parkinson's disease (OR 1.14, 95% CI 0.95-1.38, I<sub>2</sub>: 65%); however, sub-group analysis revealed a significant relationship between the disease and progestogen (OR 3.41, 95% CI 1.23 - 9.46) or combined estrogen-progestogen formulation use (OR 1.49, 95% CI 1.34 - 1.65). Indeed, this association was also found to be driven by duration of exposure (Coef<sub>1</sub> =0.0626, p<sub>1</sub>=0.04). This study reveals a significant direct relationship between the use of certain hormonal therapies and Alzheimer's disease, all-cause dementia, and Parkinson's disease in menopausal women. However, the association appears to shift in direct after five years in the context of Alzheimer's disease, adding further weight to the critical window or timing hypothesis of neurodegeneration and neuroprotection.

**Keyword:** Hormone therapy; Menopause; Alzheimer's disease; Parkinson's disease.

## 1. Introduction

Alzheimer's disease and Parkinson's disease remain the most prevalent neurodegenerative disorders worldwide (1). While the two diseases are entirely distinct in their pathogenesis, they occasionally converge upon the coexistence of dementia. Dementia is a clinical syndrome of major cognitive impairment with a variety of underlying etiologies, the most common being Alzheimer's disease, with several other vascular causes following in prevalence and Parkinsonian-related dementia representing a relatively uncommon but further debilitating presentation of the syndrome. While

there exist several competing or complementary hypotheses on the development of Alzheimer's and Parkinson's disease, the exact underlying etiologies remain uncertain and no single lifestyle or genetic factor can be implicated at present. Interestingly, however, Alzheimer's and dementia are notably imbalanced between sexes, with significantly higher prevalence and indeed incidence rates in females

(2). Although female longevity goes some of the way in explaining this prevalence disparity, researchers have now begun to query the involvement of sex-dependent hormones in the pathogenesis of these diseases.

The vasomotor symptomatology which so often accompanies the menopause can be debilitating and life-limiting for certain women. In line with this, the use of hormone therapy (HT) to negate such symptoms has become commonplace due to the ease of administration and efficacy of such treatments (3, 4). These therapies involve the application of estrogen, or its bioequivalent form, either alone or in combination with progesterone or its synthetic forms (3, 4). The results of the Women's Health Initiative indicate that while HT is an effective treatment for menopausal symptom reduction, there are various risks associated with their use which are not entirely negligible (5). For example, while it was suggested that HT may decrease risk of hip fracture and colorectal cancer, there also appears to be an increased risk of breast cancer and stroke (5). However, the impact of hormone replacement therapy on risk of cognitive impairment and neurodegenerative disorders remains highly contentious (6).

Although a number of studies have been conducted to examine the relationship between HT and the aforementioned neurodegenerative disorders, the results remain inconsistent and fail to bring consensus to the field. In order to address these inconsistencies in the literature and to further explore factors which potentially may drive these discrepancies, we performed a time-response meta-analysis evaluating the influence of menopausal HT on Alzheimer's disease, Parkinson's disease and all-cause dementia development.

## **2. Materials and methods**

### ***2.1. Search Strategy***

The MOOSE were followed to conduct this meta-analysis (7). A comprehensive systematic literature searches of related studies was conducted in PubMed/MEDLINE, Scopus, and Cochrane databases from inception to September 2019. Supplementary Table 1 outlines the specific search strategies applied for each database. The references from relevant papers were examined to identify any

additional studies and an email alert service was activated in order to avoid missing any new articles published after the completion of our systematic search.

## ***2.2. Inclusion criteria***

Studies which met the following inclusion criteria were considered for this review: 1) authors investigated the association between menopausal HT and Alzheimer's disease, dementia, or Parkinson's disease; 2) used a case-control, controlled trial, or cohort design; 3) reported appropriate estimates for outcomes or provided the data required for derivation of these estimates. All review papers, editorials, letter to editor, non-human studies, *in vitro* research, case reports, ecological studies, or letters without sufficient data were excluded from this study.

## ***2.3. Data extraction and quality assessment***

Screening of studies was conducted using a predesigned screening form and two independent authors screened studies according to the inclusion criteria in a two step process: title and/or abstract screening, followed by full text screening. Any discrepancies which arose during screening were resolved by senior author. Subsequently, two authors independently extracted the following relevant data from the included studies: first author, year of publication, study location, type of used hormone, design of study, number of participants, age, identified confounding factors, and summary estimates with 95% CIs of Alzheimer's disease, dementia, and Parkinson's disease. The fully adjusted models were used for all analysis in this study. The Newcastle-Ottawa Quality Assessment Scale (NOS) used to quality assessment of the included studies (8).

## ***2.4. Statistical analysis***

All statistical analyses in this meta-analysis were performed using STATA 14.0 statistical software (Stata Corporation, College Station, Texas, USA). The random-effects model (DerSimonian and Laird) was applied in order to combine outcomes results (9). The mean (or median) in each category of HT was considered as the reference category, when authors did not provide this data. Heterogeneity among results of included studies was estimated with Cochran's Q test and I<sup>2</sup> statistic. Meta-regressions based on baseline age of participants and subgroup analysis of HT based on design of primary study, as well as the type of hormone used, were conducted to identify potential sources of heterogeneity. In addition, sensitivity analysis was run to examine the effect of each study on the pooled result. The trim and fill approach was used to adjust for publication bias among included



studies. Potential curvilinear associations between duration of HT and incidence of Alzheimer's disease, dementia, and Parkinson's disease were evaluated with three knots in 10%, 50%, and 90% of the distribution by restricted cubic splines method(10). Finally, publication bias was evaluated using the funnel plot, Begg's and Egger's test.

### **3. Results**

#### ***3.1. Literature search***

Figure 1 presents a flow chart of the systematic search and inclusion of studies in this meta-analysis. through this comprehensive systematic search of PubMed/Medline, Scopus, and Cochrane collaboration databases, 731 papers were initially identified, of which 216 were found to be duplicates. From remaining studies, 480 papers failed to meet the inclusion criteria and were excluded during title and/or abstracts screening, while an additional seven records were excluded following full text evaluation. Ultimately, 28 papers were included in this meta-analysis (11-38).

#### ***3.2. Study characteristics and quality assessment***

Table 1 displays the relevant information of all included studies. The studies, which were published between 1994-2019, included 14 case-control studies (11, 13, 15, 22, 26-28, 30-34, 37, 38), two RCTs (14, 19), and 12 cohort studies (12, 16-18, 20, 21, 23-25, 29, 35, 36). The primary locations included USA, UK, Finland, Denmark, France, Italy, and Canada. No participants with a prior diagnosis of Alzheimer's disease, dementia, or Parkinson's disease at baseline were included in the cohort studies or RCTs included. The studies examined applied hormone therapies which were composed of estrogen, progesterone (or its derivatives), or a combined formulation of the two hormones. The majority of included studies were found to be of high quality according to Supplemental Table 2, with 11 returning a score of nine (12, 16, 17, 20-22, 24, 27, 33, 35, 38).

#### ***3.3. Association of HT use with neurodegenerative disease***

Fourteen studies containing 19 arms reported on the relationship between HT and Alzheimer's disease as outcome measure (11, 12, 20, 24, 26, 29-32, 34-38). The pooled OR (95% CI) in the hormone-treated versus hormone-naïve was OR 1.08 for Alzheimer's disease (95% CI 1.03 -1.14, I<sup>2</sup>: 69%) (Fig. 2). Furthermore, five studies with nine arms reported dementia OR as their outcome measure (14, 19, 21, 24, 25) and the combined analysis identified a significant direct relationship between HT use and

dementia (OR 1.16, 95% CI 1.02 -1.31, I<sub>2</sub>: 19%). Finally, in ten studies with 22 arms (15-19, 22, 23, 27, 28, 33) the association between Parkinson's disease in HT was not found to be significant (OR 1.14, 95% CI 0.95-1.38, I<sub>2</sub>: 65%).

### ***3.4. Association of HT formulation with neurodegenerative disease***

We subsequently stratified studies for Alzheimer's disease and Parkinson's disease based on the formulation of used hormone (Figure 3) and the design of the primary studies (Supplementary Fig. 1). These analyses showed that different hormone have varying effects on disease occurrence (heterogeneity between group was  $p=0.005$  for Alzheimer's disease results and  $p=0.002$  for Parkinson's disease). Indeed, the relationship between HT and Alzheimer's disease was found to be stronger in patients using the combined estrogen-progestogen formulation (OR 1.16, 95% CI 1.12 - 1.21), while progestogen only (OR 1.13, 95% CI 1.10 - 1.17) and estrogen only therapies remained associated with the disease, but displayed a slightly less concerning effect level (OR 1.09, 95% CI 1.06 - 1.11). The relationship between HT and Parkinson's disease was found to be strongest in patients using the progestogen only therapy (OR 3.41, 95% CI 1.23 - 9.46), while the combined estrogen-progestogen formulation also displayed disease association, but again with a more modest effect size (OR 1.49, 95% CI 1.34 - 1.65). Interestingly, our meta-analysis suggests that estrogen-only formulations have no significant associations with Parkinson's disease development (OR 1.08, 95% CI 0.90 - 1.22).

### ***3.5. Effect of study design on HT-neurodegenerative disease interaction***

Interestingly, while a significant relationship was identified between HT and Alzheimer's disease in the included case-control studies (OR 1.12, 95% CI 1.10 - 1.13), no such effect was detected in the included cohort studies (OR 0.89, 95% CI 0.76 - 1.04). Conversely, the relationship between HT and Parkinson's disease was significant in cohort studies (OR 1.39, 95% CI 1.28 - 1.52) and not the included case-control studies (OR 0.96, 95% CI 0.74 - 1.26). Moreover, the relationship between HT and dementia was significant in the included RCTs (OR 1.16, 95% CI 1.02 - 1.32), but the same effect was not achieved in the included cohort studies (OR 1.13, 95% CI 0.97 - 1.33). Finally, meta-regression based on baseline age of participants did not reveal this variable as a source of heterogeneity for Alzheimer's disease, Parkinson's disease, or dementia diagnosis (Supplemental Fig 2).

### ***3.6. Time-response analysis***

A significant association between duration of HT and Alzheimer's disease, which is direct in initial five years and inverse in subsequent years (Coef<sub>1</sub> =0.0477, p<sub>1</sub><0.001; Coef<sub>2</sub> = -0.0932, p<sub>2</sub><0.001), was noted in the present meta-analysis (Fig 4). The combined OR was significant and direct between duration of HT and Parkinson's disease in first 5 years of HT (Coef<sub>1</sub> =0.0626, p<sub>1</sub>=0.04), but non-significant in years afterwards (Coef<sub>2</sub> = -0.0427, p<sub>2</sub>=0.21).

### **3.7. Publication bias**

Supplementary Figure 3 includes funnel plots which indicate that there was publication bias among the studies reporting on Alzheimer's disease (Begg's p=0.17 and Egger regression test p=0.02), but not for dementia (Begg's p=0.67 and Egger regression test p=0.77) or Parkinson's disease (Begg's p=0.59 and Egger regression test p=0.05). The 'trim and fill' method was applied in order to adjust for publication bias identified in Alzheimer's disease reporting studies (Supplemental Table 3). Finally, the sensitivity analysis does not show significant differences beyond the limits of 95% CI of calculated combined results for each of included studies (Supplemental Fig 4).

## **4. Discussion**

HT represents a stalwart of symptomatic management in menopausal women and while such therapies have demonstrated unparalleled efficacy in this application, their association with neurodegenerative disease remains equivocal. As a result, we sought to determine the relationship between menopausal HT and Alzheimer's disease, all-cause dementia, and Parkinson's disease in human subjects. The present meta-analysis, which included data from case-control, controlled trial and cohort design studies, found that HT-use was significantly associated with development of Alzheimer's disease and dementia of undefined etiology, whilst no such effect was uncovered for Parkinson's disease. In addition, sub-group analysis revealed that combined estrogen-progestogen formulations produced higher odds of Alzheimer's disease when compared to therapies containing progestogen, estrogen or estradiol alone. With respect to Parkinson's disease, progestogen only and combined estrogen-progestogen formulations were significantly associated with the disease while other therapies were not. Finally, we reveal a significant direct association between duration of HT with Alzheimer's and Parkinson's disease in the first five years of treatment.

A number of observational investigations have previously reported a significant Alzheimer's disease and dementia risk reduction in those prescribed HT (20, 39-42). However, questions remain around the veracity and generalizability of these findings, as the original studies generally lack sufficient

control and selection bias towards healthy females may have existed in HT groups. Indeed, this suspicion was supported by the results of the placebo-controlled WHIMS trial, in which the authors observed an increased risk of impaired cognition and dementia in women using certain forms of HT (43, 44). However, the design of the WHIMS trial itself has not been free of criticism, since HT was commenced more than a decade on from the typical age of menopausal onset, a practice which is not the standard. In addition, the WHIMS cohort were not differentiated according to etiology of cognitive decline and it is conceivably that each process may respond differently to HT exposure (43, 44). Importantly, a recently updated Cochrane review by Marjoribanks et al. concluded that HT is not suitable for the prevention of dementia or cognitive decline in postmenopausal women (45). This lack of protection is an important message to disseminate considering the results of the present meta-analysis, which indicates that HT may in fact be a contributory factor in the development of such neurodegenerative diseases.

Although a number of histological characteristics have been identified as osthumous hallmarks of the pathology, the precise underlying cause of Alzheimer's disease is not entirely understood (46, 47). As a result, it remains a challenge to pinpoint the mechanisms through which HT may interact with the disease, be it in a beneficial or harmful manner. However, it has been reported that the risk of Alzheimer's disease may increase in a graded fashion with each full-term pregnancies, an effect which is postulated to be the result of repeated exposure to estrogen-progesterone surges (48). Conversely, several mechanisms exist through which HT may be considered to protect against the disease, including improvements in cerebral blood flow (49, 50), increases in dendritic spine density (51-53), and nerve growth factor interactions (54). A narrative which arose from cardiovascular outcome observations around HT suggest that there may be an important temporal nature to the interaction. Specifically, it is suggested that estrogen may only be neuroprotective if initiated soon after menopausal onset, a theory which largely arose following the WHIMS trials revelations. This speculative hypothesis, otherwise termed the 'critical window' theory, has support in animal-based models (55). The evidence from animal models suggests that HT during the 'critical window' is linked to neuroprotection through reduced deposition of  $\beta$ -amyloid, synaptic formation improvements, increased choline acetyltransferase activity, and improvements in cerebral perfusion (56-58). This 'critical window' hypothesis may explain why HT beyond the initial five years was inversely associated with incidence in the context of Alzheimer's disease.

Investigations into the use of HT and risk for Parkinson's disease have yielded inconsistent findings, which suggests that the interaction between HT and Parkinson's disease is complex and multi-faceted

(27, 59-63). Indeed, in the present study, we found no significant association between HT and Parkinson's disease. Despite this, sub-group analysis of specific HT types revealed a significantly higher risk of Parkinson's disease development in those treated with progestogen and combined estrogen-progestogen formulations. Although this putative relationship indeed warrants further elucidation, it is important to note that just a single study examined the effect of progesterone-only HT on Parkinson's disease. Therefore, this result should be replicated, preferably in an RCT setting, before this phenomenon is to be treated as reliable.

In the present mixed-source meta-analysis, we further examined the effect of data origin on the association of HT with neurodegenerative disease through stratification by study design. According to the hierarchy of evidence, RCT-derived data represents the most reliable form of information, while case-control and cohort design studies are inferior but relatively equal in their veracity. In the context of Alzheimer's disease, we found that the association with HT was maintained following meta-analysis of case control studies in isolation; however, no such effect was observed when cohort studies were examined independently. Contrastingly, when Parkinson's studies were stratified, we found that cohort-derived data showed a significant effect, while case control studies did not. Finally, in the case of dementia, meta-analysis of RCT data maintained the same effect size and direction, while cohort study-specific meta-analysis revealed no significant association. These results indicate that, while there was a degree of discord amongst study designs, there was no consistent and substantial impact of design on the overall study outcome. In addition, we can be reassured by the fact that no sub-group meta-analysis revealed a significant opposing effect and the RCT-specific meta-analysis of all-cause dementia is in keeping with the overall result.

### *Strengths and limitations*

There are a number of significant strengths of the present work which are important to note. Firstly, the present study has provided better clarity into the effect of HT on Alzheimer's disease, all-cause dementia and Parkinson's disease, by integrating results from 14 case-control (11, 13, 15, 22, 26-28, 30-34, 37, 38), two were RCTs (14, 19), and 12 cohort studies (12, 16-18, 20, 21, 23-25, 29, 35, 36). Furthermore, the sensitivity analysis showed no significant differences beyond the limits of 95% CI of calculated combined results for each of included studies, suggesting that their inclusion was justified and the findings are reliable. Despite the aforementioned strengths, this meta-analysis also possesses several limitations. Although the total included population of pooled participants in the present meta-analysis is considerable, the sample size of several individual studies was relatively small. It is

conceivable that a small sample size may influence the detection of rare outcomes, particularly in relation to less common neurodegenerative diseases (64). Furthermore, the dose and timing may represent impactful factors in determining the neuroprotective or neurodegenerative effects of such treatments and, although we explored the temporal effects, we have not explored any potential dose-response associations. We must also recognise the substantial weight which was attributed to a small number of studies in the Alzheimer's disease meta-analysis. Although weight to each study was related to sample size and precision of that study, as is the gold standard practice of meta-analysis, this has resulted in a disproportionate representation of a select number of studies. Furthermore, we did not have any RCT-derived data to draw from for the Alzheimer's disease and Parkinson's disease meta-analysis. It is recommended that double-blind RCTs be conducted in order to confirm the veracity of our findings, although ethical concerns must be carefully managed in this instance.

## **5. Conclusion**

This study revealed a significant and direct relationship between HT and Alzheimer's disease or all-cause dementia in postmenopausal women. However, this effect is limited to the first five years of therapy in Alzheimer's disease and in fact the direction of association appears to reverse in the years to follow. In addition, certain formulations of HT were found to be associated with an elevated risk of Parkinson's disease. Although this study integrated data from both observational and controlled trial study designs, the results remain consistent and indicate that large-scale RCT investigations into the long-term safety of different HTs in the context of neurodegenerative disease and cognitive decline are urgently required.

### **Conflict of Interest**

The authors declare that they have no conflict of interest.

## **References**

1. Erkinen MG, Kim MO, Geschwind MD. Clinical Neurology and Epidemiology of the Major Neurodegenerative Diseases. *Cold Spring Harbor Perspectives Biol.* 2018;10(4).
2. Andersen K, Launer LJ, Dewey ME, Letenneur L, Ott A, Copeland JR, et al. Gender differences in the incidence of AD and vascular dementia: The EURODEM Studies. EURODEM Incidence Research Group. *Neurology.* 1999;53(9):1992-7.

3. Kutlešić RM, Popović J, Stefanović M, Vukomanović P, Andrić A, Milošević J. Menopausal hormone therapy: Benefits and different forms. *Medicinski pregljed*. 2016;69(7-8):247-54.
4. Davey D. Menopausal hormone therapy: a better and safer future. *Climacteric*. 2018;21(5):454-61.
5. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. *Jama*. 2002;288(3):321-33.
6. Dye RV, Miller KJ, Singer EJ, Levine AJ. Hormone replacement therapy and risk for neurodegenerative diseases. *International journal of Alzheimer's Disease*. 2012;2012.
7. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. *Jama*. 2000;283(15):2008-12.
8. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. *European journal of epidemiology*. 2010;25(9):603-5.
9. Jackson D, White IR, Thompson SG. Extending DerSimonian and Laird's methodology to perform multivariate random effects meta-analyses. *Statistics in medicine*. 2010;29(12):1282-97.
10. Harre Jr FE, Lee KL, Pollock BG. Regression models in clinical studies: determining relationships between predictors and response. *JNCI: Journal of the National Cancer Institute*. 1988;80(15):1198-202.
11. Savolainen-Peltonen H, Rahkola-Soisalo P, Hoti F, Vattulainen P, Gissler M, Ylikkala O, et al. Use of postmenopausal hormone therapy and risk of Alzheimer's disease in Finland: nationwide case-control study. *BMJ (Clinical research ed)*. 2019;364:l665.
12. Imtiaz B, Tuppurainen M, Rikkonen T, Kivipelto M, Soininen H, Kroger H, et al. Postmenopausal hormone therapy and Alzheimer disease: A prospective cohort study. *Neurology*. 2017;88(11):1062-8.
13. Imtiaz B, Taipale H, Tanskanen A, Tiihonen M, Kivipelto M, Hiltunen AM, et al. Risk of Alzheimer's disease among users of postmenopausal hormone therapy: A nationwide case-control study. *Maturitas*. 2017;98:7-13.
14. Espeland MA, Brinton RD, Hugeschmidt C, Manson JE, Craft S, Yaffe K, et al. Impact of Type 2 Diabetes and Postmenopausal Hormone Therapy on Incidence of Cognitive Impairment in Older Women. *Diabetes Care*. 2015;38(12):2316-24.
15. Lundin JI, Ton TG, Lacroix AZ, Longstreth WT, Franklin GM, Swanson PD, et al. Formulations of hormone therapy and risk of Parkinson's disease. *Movement Disorders*. 2014;29(13):1631-6.
16. Liu R, Baird D, Park Y, Freedman ND, Huang X, Hollenbeck A, et al. Female reproductive factors, menopausal hormone use, and Parkinson's disease. *Movement disorders : official journal of the Movement Disorder Society*. 2014;29(7):889-96.
17. Gatto NM, Deapen D, Stoyanoff S, Pinder R, Narayan S, Bordelon Y, et al. Lifetime exposure to estrogens and Parkinson's disease in California teachers. *Parkinsonism & related disorders*. 2014;20(11):1149-56.
18. Rugbjerg K, Christensen J, Tjønneland A, Olsen JH. Exposure to estrogen and women's risk for Parkinson's disease: a prospective cohort study in Denmark. *Parkinsonism & related disorders*. 2013;19(4):457-60.
19. Manson JE, Chlebowski RT, Stefanick ML, Aragaki AK, Rossouw JE, Prentice RL, et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials. *Jama*. 2013;310(13):1353-68.
20. Shao H, Breitner JC, Whitmer RA, Wang J, Hayden K, Wengreen H, et al. Hormone therapy and Alzheimer disease dementia: new findings from the Cache County Study. *Neurology*. 2012;79(18):1846-52.
21. Whitmer RA, Quesenberry CP, Zhou J, Yaffe K. Timing of hormone therapy and dementia: the critical window theory revisited. *Annals of neurology*. 2011;69(1):163-9.

22. Nicoletti A, Nicoletti G, Arabia G, Annesi G, De Mari M, Lamberti P, et al. Reproductive factors and Parkinson's disease: a multicenter case-control study. *Movement disorders : official journal of the Movement Disorder Society*. 2011;26(14):2563-6.
23. Simon KC, Chen H, Gao X, Schwarzschild MA, Ascherio A. Reproductive factors, exogenous estrogen use, and risk of Parkinson's disease. *Movement disorders : official journal of the Movement Disorder Society*. 2009;24(9):1359-65.
24. Ryan J, Carriere I, Scali J, Dartigues JF, Tzourio C, Poncet M, et al. Characteristics of hormone therapy, cognitive function, and dementia: the prospective 3C Study. *Neurology*. 2009;73(21):1729-37.
25. Petitti DB, Crooks VC, Chiu V, Buckwalter JG, Chui HC. Incidence of dementia in long-term hormone users. *Am J Epidemiol*. 2008;167(6):692-700.
26. Roberts RO, Cha RH, Knopman DS, Petersen RC, Rocca WA. Postmenopausal estrogen therapy and Alzheimer disease: overall negative findings. *Alzheimer disease and associated disorders*. 2006;20(3):141-6.
27. Popat R, Van Den Eeden S, Tanner C, McGuire V, Bernstein A, Bloch D, et al. Effect reproductive factors and postmenopausal hormone use on the risk of Parkinson disease. *Neur I gy*. 2005;65(3):383-90.
28. Currie LJ, Harrison MB, Trugman JM, Bennett JP, Wooten GF. P stmen pausal estrogen use affects risk for Parkinson disease. *Arch Neurol*. 2004;61(6):886-8.
29. Lindsay J, Laurin D, Verreault R, Hébert R, Helliwell B, Hill GB, et al. Risk factors for Alzheimer's disease: a prospective analysis from the Canadian Study of Health and Aging. *American journal of epidemiology*. 2002;156(5):445-53.
30. Seshadri S, Zornberg GL, Derby LE, Myers MW, Jick H, Drachman DA. Postmenopausal estrogen replacement therapy and the risk of Alzheimer disease. *Arch N urol*. 2001;58(3):435-40.
31. Benedetti MD, Maraganore DM, Bower JH, McDonn II SK, Peterson BJ, Ahlskog JE, et al. Hysterectomy, menopause, and estrogen use preceding Pa kinson's disease: an exploratory case-control study. *Movement disorders : official journal of the Movement Disorder Society*. 2001;16(5):830-7.
32. Waring SC, Rocca WA, Petersen RC, O'Brien C, Tangalos EG, Kokmen E. Postmenopausal estrogen replacement therapy and risk of AD: a population-based study. *Neurology*. 1999;52(5):965-70.
33. Marder K, Tang M-X, Alfaró B, Mejia H, Cote L, Jacobs D, et al. Postmenopausal estrogen use and Parkinson's disease with and without dementia. *Neurology*. 1998;50(4):1141-3.
34. Baldereschi M, Di Carlo A, Lepore V, Bracco L, Maggi S, Grigoletto F, et al. Estrogen-replacement therapy and Alzheimer's disease in the It li n Longitudinal Study on Aging. *Neurology*. 1998;50(4):996-1002.
35. Kawas C, Resnick S, Mo rison A, Brookmeyer R, Corrada M, Zonderman A, et al. A prospective study of estrogen replacement therapy and the risk of developing Alzheimer's disease: the Baltimore Longitudinal St dy of Aging. *Neu ology*. 1997;48(6):1517-21.
36. Tang MX, Jacobs D, Stern Y, Marder K, Schofield P, Gurland B, et al. Effect of oestrogen during menopause n risk and age at onset of Alzheimer's disease. *Lancet (London, England)*. 1996;348(9025):429-32.
37. Paganini-Hill A, Henderson VW. Estrogen replacement therapy and risk of Alzheimer disease. *Arch Intern Med*. 1996;156(19):2213-7.
38. Brenner DE, Kukull WA, Stergachis A, van Belle G, Bowen JD, McCormick WC, et al. Postmenopausal estrogen replacement therapy and the risk of Alzheimer's disease: a population-based case-control study. *Am J Epidemiol*. 1994;140(3):262-7.
39. Tang M-X, Jacobs D, Stern Y, Marder K, Schofield P, Gurland B, et al. Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease. *The Lancet*. 1996;348(9025):429-32.
40. Waring SC, Rocca WA, Petersen RC, O'Brien P, Tangalos EG, Kokmen E. Postmenopausal estrogen replacement therapy and risk of AD: a population-based study. *Neurology*. 1999;52(5):965-.



41. Zandi PP, Carlson MC, Plassman BL, Welsh-Bohmer KA, Mayer LS, Steffens DC, et al. Hormone replacement therapy and incidence of Alzheimer disease in older women: the Cache County Study. *Jama*. 2002;288(17):2123-9.
42. Imtiaz B, Taipale H, Tanskanen A, Tiihonen M, Kivipelto M, Heikkinen A-M, et al. Risk of Alzheimer's disease among users of postmenopausal hormone therapy: A nationwide case-control study. *Maturitas*. 2017;98:7-13.
43. Shumaker SA, Legault C, Rapp SR, Thal L, Wallace RB, Ockene JK, et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. *Jama*. 2003;289(20):2651-62.
44. Shumaker SA, Legault C, Kuller L, Rapp SR, Thal L, Lane DS, et al. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study. *Jama*. 2004;291(24):2947-58.
45. Marjoribanks J, Farquhar C, Roberts H, Lethaby A. Long term hormone therapy for perimenopausal and postmenopausal women. *Cochrane Database of Systematic Reviews*. 2012(7).
46. Mucke L, Selkoe DJ. Neurotoxicity of amyloid  $\beta$ -protein: synaptic and network dysfunction. *Cold Spring Harbor perspectives in medicine*. 2012;2(7):a006338.
47. Zempel H, Mandelkow E. Lost after translation: missorting of Tau protein and consequences for Alzheimer disease. *Trends in neurosciences*. 2014;37(12):721-32.
48. Jang H, Bae JB, Dardiotis E, Scarmeas N, Sachdev PS, Lipnicki DM, et al. Differential effects of completed and incomplete pregnancies on the risk of Alzheimer disease. *Neurology*. 2018;91(7):e643-e51.
49. Crook D, Meire H, Gangar K, Vyas S, Whitehead M, Campbell S. Pulsatility index in internal carotid artery in relation to transdermal oestradiol and time since menopause. *The Lancet*. 1991;338(8771):839-42.
50. Penotti M, Nencioni T, Gabrielli L, Farina M, Castiglioni E, Polvani F. Blood flow variations in internal carotid and middle cerebral arteries induced by postmenopausal hormone replacement therapy. *American journal of obstetrics and gynecology*. 1993;169(5):1226-32.
51. Gould E, Woolley CS, Frankfurt M, McEwen BS. Gonadal steroids regulate dendritic spine density in hippocampal pyramidal cells in adulthood. *Journal of Neuroscience*. 1990;10(4):1286-91.
52. Woolley CS, Gould E, Frankfurt M, McEwen BS. Naturally occurring fluctuation in dendritic spine density on adult hippocampal pyramidal neurons. *Journal of neuroscience*. 1990;10(12):4035-9.
53. Woolley CS, McEwen BS. Roles of estradiol and progesterone in regulation of hippocampal dendritic spine density during the estrous cycle in the rat. *Journal of Comparative Neurology*. 1993;336(2):293-306.
54. Toran-Allerand CD, Miranda RC, Bentham W, Sohrabji F, Brown TJ, Hochberg RB, et al. Estrogen receptors colocalize with low-affinity nerve growth factor receptors in cholinergic neurons of the basal forebrain. *Proceedings of the National Academy of Sciences*. 1992;89(10):4668-72.
55. Petitti DB, Crooks VC, Chiu V, Buckwalter JG, Chui HC. Incidence of dementia in long-term hormone users. *American journal of epidemiology*. 2008;167(6):692-700.
56. Bernardi F, Pluchino N, Stomati M, Pieri M, Genazzani A. CNS: sex steroids and SERMs. *Annals of the New York Academy of Sciences*. 2003;997(1):378-88.
57. Gibbs RB. Estrogen and Nerve Growth Factor - related Systems in Brain: Effects on Basal Forebrain Cholinergic Neurons and Implications for Learning and Memory Processes and Aging. *Annals of the New York Academy of Sciences*. 1994;743(1):165-96.
58. McEwen BS, Gould E, Orchinik M, Weiland NG, Woolley CS, editors. Oestrogens and the structural and functional plasticity of neurons: implications for memory, ageing and neurodegenerative processes. *Ciba Foundation Symposium 191 - Non - Reproductive Actions of Sex Steroids: Non - Reproductive Actions of Sex Steroids: Ciba Foundation Symposium 191; 2007: Wiley Online Library*.

59. Brann DW, Dhandapani K, Wakade C, Mahesh VB, Khan MM. Neurotrophic and neuroprotective actions of estrogen: basic mechanisms and clinical implications. *Steroids*. 2007;72(5):381-405.
60. Ascherio A, Chen H, Schwarzschild M, Zhang S, Colditz G, Speizer F. Caffeine, postmenopausal estrogen, and risk of Parkinson's disease. *Neurology*. 2003;60(5):790-5.
61. Twelves D, Perkins KS, Counsell C. Systematic review of incidence studies of Parkinson's disease. *Movement disorders: official journal of the Movement Disorder Society*. 2003;18(1):19-31.
62. Nicoletti A, Nicoletti G, Arabia G, Annesi G, De Mari M, Lamberti P, et al. Reproductive factors and Parkinson's disease: A multicenter case-control study. *Movement Disorders*. 2011;26(14):2563-6.
63. Ragonese P, D'amelio M, Salemi G, Aridon P, Gammino M, Epifanio A, et al. Risk of Parkinson disease in women: effect of reproductive characteristics. *Neurology*. 2004;62(11):2010-4.
64. Suresh K, Chandrashekar S. Sample size estimation and power analysis for clinical research studies. *Journal of human reproductive sciences*. 2012;5(1):7.

Fig 1. Flow chart of included studies.






Figure 2. The ratio of:

a) Alzheimer's disease



b) Dementia



c) Parkinson's disease





Figure 3. The forest plot of s bgro p analysis of Hormone therapy based on type of used hormone and odd ratio of:  
a) Alzheimer's disease



b) Parkinson's disease






Figure 4. The Duration-response analysis of hormone therapy and odd ratio of:

a) Alzheimer's disease



b) Parkinson's disease





**Table 1. Characteristics of included studies**

Author	Year	Location	Type of hormone used	Design of study	Age	Participants (n)	Outcome
Savolainen-Peltonen, H.	2019	Finland	Estradiol and Combination	case-control	-	169478	Alzheimer's disease
Imtiaz, B.	2017	Finland	Estrogen and Combination	cohort	72.3	8195	Alzheimer's disease
Imtiaz, B. (b)	2017	Finland	Estrogen and Progestogen	case-control	81	230580	Alzheimer's disease
Espeland, M. A.	2015	USA	Estrogen and Progestogen	RCT	71	7233	Dementia

Lundin, J. I.	2014	USA	Estrogen and Combination	case-control	68	305	Parkinson's disease
Lindsay, Joan	2002	Canada	Estrogen	Cohort	65<	2208	Alzheimer's disease
Liu, R.	2014	USA	Estrogen and Combination	Cohort	61	119166	Parkinson's disease
Gatto, N. M.	2017	USA	Estrogen and Combination	Cohort	61	2772	Parkinson's disease
Rugbjerg, K.	2013	Denmark	Estrogen and Combination	Cohort	66.6	27466	Parkinson's disease
Manson, J. E.	2013	USA	Estrogen and Combination	RCT	65<		Dementia
Shao, Huibo	2012	USA	Hormone therapy	cohort	74	1768	Alzheimer's disease
Whitmer, R.	2011	USA	Hormone therapy	cohort	48	5504	Dementia
Nicoletti, A.	2011	Italy	Hormone therapy	case-control	64	499	Parkinson's disease
Simon, K.	2009	USA	Estrogen, Progesterone and Combination	Cohort	65.7	121701	Parkinson's disease
Ryan, J.	2009	French	Hormone therapy	cohort	65<	3130	Alzheimer's disease, Dementia
Petitti, D. B.	2008	USA	Estrogen and Combination	cohort	78.7	2906	Dementia
Roberts, R. O.	2006	USA	Estrogen	case-control	-	528	Alzheimer's disease

Popat, RA	2005	USA	Hormone therapy	case-control	-	367	Parkinson's disease
Currie, L. J.	2005	USA	Estrogen	case-control	50	140	Parkinson's disease
Seshadri, S.	2001	UK	Hormone therapy	case-control	65	280	Alzheimer's disease
Benedetti, M. D.	2001	USA	Estrogen	case-control	-	144	Alzheimer's disease
Waring, S. C.	1999	USA	Estrogen	case-control	50	222	Alzheimer's disease
Marder, Karen	1998	USA	Estrogen	case-control	-	1156	Parkinson's disease
Kawas, C.	1997	USA	Estrogen	cohort		472	Alzheimer's disease
Baldereschi, M.	1998	Italy	Estrogen	case control	-	1568	Alzheimer's disease
Tang, M. X.	1996	USA	Estrogen	cohort	74.2	1282	Alzheimer's disease
Paganini-Hill, A.	1996	USA	Estrogen	case-control	87	1439	Alzheimer's disease
Brenner, D. E.	1994	USA	Estrogen	case-control	77	227	Alzheimer's disease

---